Alexza's Adasuve crosses US finish line, but distribution limited

Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.

Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.

Mountain View, California-based Alexza's stock closed at $5.79, a loss of 6.7%, or 4 cents. But in after-hours trading, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Therapeutic Category

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza